Andreas Schrock

Bonn, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

CD3 and PD-L1 tissue expression have synergistic value in head and neck squamous cell carcinoma prognosis.

CD3 and PD-L1 tissue expression have synergistic value in head and neck squamous cell carcinoma prognosis.

Journal: Translational oncology

Published: November 13, 2025

Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion.

Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 12, 2020

Cross-sectional increase of adherence to multidisciplinary tumor board decisions.

Cross-sectional increase of adherence to multidisciplinary tumor board decisions.

Journal: BMC cancer

Published: January 31, 2018

Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas.

Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas.

Journal: PloS one

Published: September 08, 2017

PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas.

PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas.

Journal: Oncotarget

Published: May 31, 2017

Interventional radiology in the head and neck region

Interventional radiology in the head and neck region

Journal: HNO

Published: April 29, 2017

Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients.

Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients.

Journal: Clinical epigenetics

Published: April 29, 2017

PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.

PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.

Journal: Oncotarget

Published: March 02, 2017

PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.

PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.

Journal: Oncotarget

Published: December 14, 2016

Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.

Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.

Journal: Clinical chemistry

Published: December 14, 2016

PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma.

PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma.

Journal: Clinical epigenetics

Published: November 27, 2016

Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.

Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.

Journal: International journal of molecular sciences

Published: November 07, 2016

Showing 1-12 of 44

Last Updated: 09/26/2026